Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353321 | 1.00 | CCNT1 (0.62) | CCNT1FLT3PIM1CDK1CDK4 | |
| SCHEMBL10323459 | 0.89 | CCNT1 (0.56) | CCNT1FLT3PIM1 | |
| SCHEMBL10353659 | 0.89 | CCNT1 (0.56) | CCNT1FLT3PIM1 | |
| SCHEMBL10353744 | 0.88 | MAPK8 (0.52) | CCNT1FLT3PIM1CDK1CDK4 | |
| SCHEMBL10323153 | 0.88 | MAPK8 (0.52) | CCNT1FLT3PIM1CDK1CDK4 | |
| SCHEMBL10353613 | 0.83 | MERTK (0.47) | CCNT1FLT3CDK1CDK4CCNB1 | |
| SCHEMBL10324055 | 0.83 | MERTK (0.47) | CCNT1FLT3CDK1CDK4CCNB1 | |
| SCHEMBL10353076 | 0.83 | FLT3 (0.48) | CCNT1FLT3PIM1 | |
| SCHEMBL10322609 | 0.83 | FLT3 (0.48) | CCNT1FLT3PIM1 | |
| SCHEMBL10353924 | 0.82 | FLT3 (0.56) | CCNT1FLT3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | claimed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | claimed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | TYMS, TYMP, TP53 | CCNT1 182/4885FLT3 1618/4885PIM1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.